A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Gemigliptin (Primary)
- Indications Acute kidney injury; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 12 Sep 2018 Primary endpoint (Gemigliptin AUC,ss Geometric Mean Ratio (and 90%CI)) has not been met, according to results published in the Clinical Therapeutics.
- 12 Sep 2018 Results published in the Clinical Therapeutics.
- 21 Oct 2017 New trial record